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Introduction: Low dose-rate radioimmunotherapy (RIT) using 125I-labelled monoclonal antibodies (125I-
mAbs) is associated with unexpected high cytotoxicity per Gy.
Methods: We investigated whether this hypersensitivity was due to lack of detection of DNA damage by the
targeted cells. DNA damage was measured with the alkaline comet assay, gamma-H2AX foci and the
micronucleus test in p53−/− and p53+/+ HCT116 cells exposed to increasing activities of internalizing anti-
HER1 125I-mAbs or non-internalizing anti-CEA 125I-mAbs. The expression of proteins involved in radiation
response and progression of cells through the cycle were determined.
Results: Cell hypersensitivity to low absorbed doses of anti-CEA 125I-mAbs was not due to defect in DNA
damage detection, since ATM (ataxia telangiectasia mutated gene), gamma-H2AX, p53 and p21 were
activated in RIT-treated HCT116 cells and G2/M cell cycle arrest was observed. Moreover, the alkaline comet
assay showed that DNA breaks accumulated when cells were placed at 4 °C during exposure but were
repaired under standard RIT conditions (37 °C), suggesting that lesions detected under alkaline conditions
(mostly DNA single strand breaks and alkali-labile sites) are efﬁciently repaired in treated cells. The level of
gamma-H2AX protein corroborated by the level of foci measured in nuclei of treated cells was shown to
accumulate with time thereby suggesting the continuous presence of DNA double strand breaks. This was
accompanied by the formation of micronuclei.
Conclusion: Hypersensitivity to non-internalizing 125I-mAbs is not due to lack of detection of DNA damage
after low absorbed dose-rates. However, DNA double strand breaks accumulate in cells exposed both to
internalizing and non-internalizing 125I-mAbs and lead to micronuclei formation. These results suggest
impairment in DNA double strand breaks repair after low absorbed doses of 125I-mAbs.
© 2014 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
Auger electrons are produced in cascades during electronic shell
rearrangement consecutive to electronic capture and/or conversion
processes in unstable atoms [1]. They have a very low energy (from a
few eV to a few keV) and are considered as high LET particles (from 4
to 26 keV/μm) when their energy is less than 1 keV. Consequently,
their path length in biological matter is very short, between about
2 nm and 500 nm for most of them (for reviews see [2–8]). Due toCancérologie de Montpellier,
Montpellier Cedex 5, France.
ouget).
-NC-ND license.their physical characteristics, efforts have been done to bring Auger
electrons in the cell nucleus to obtain the highest cytotoxicity (for
review [5]).
However, although clinical radioimmunotherapy (RIT) studies
using Auger electrons labeled to monoclonal antibodies (mAbs) have
not given clear-cut results [9–12], we and others have shown that, in
mice, Auger electrons could efﬁciently delay growth of small solid
tumors [13–18]. This efﬁcacy remains to be elucidated because the
ﬁnal localization of 125I-mAbs (and the subsequent energy deposit
[19]) upon binding to their receptors is the cell membrane (non-
internalizing mAbs) or the cytoplasm (internalizing mAbs) after a
receptor-mediated internalizing process. Therefore, for both types of
mAbs, most of the energy is released in extra-nuclear compartments.
Moreover, we previously reported in several cell lines that non-
internalizing 125I-mAbs are more toxic than internalizing 125I-mAbs
e76 B. Piron et al. / Nuclear Medicine and Biology 41 (2014) e75–e83[19,20]. This higher cytotoxicity is p53-independent (differently from
internalizing 125I-mAbs) and does not involve cell membrane-
mediated apoptotic mechanisms [19].
In conventional external beam radiation therapy (CEBRT), the
nucleus is the key target of ionizing irradiation. However, the
comparison between CEBRT and RIT is not straightforward. Indeed,
CEBRT delivers high radiation doses (between 40 and 80 Gy) at high
dose-rate (1–2 Gy.min−1) that are fractionated in daily 2 Gy doses
and the biological response to CEBRT is correlated with both dose and
dose-rate [21,22]. The cell response to radiation is mostly triggered
by DNA double strand breaks (DSBs) the occurrence of which is
strictly proportional to the mean nucleus absorbed dose [21]. DSBs
initiate different signaling pathways that involve ATM, a DNA
damage sensor molecule. In turn, ATM activates proteins (particu-
larly, H2AX and p53) that participate in cell cycle arrest, apoptosis
and DNA repair (for reviews see [23–26]). Conversely, RIT is
characterized by protracted exposure (hours to days), resulting in
low total doses (10–30 Gy compared to 40–80 Gy in EBRT) delivered
at low dose-rates (b1Gy.h−1), and is accompanied by a strong
heterogeneity in subcellular energy deposits. These physical features
provide cancer cells with an opportunity for DNA repair during RIT.
However, several studies in mice have shown that RIT cytotoxicity
per unit of absorbed dose is higher than that of a single fraction of
radiation delivered at higher dose-rate in CEBRT [27,28]. Hypotheses
have been proposed for explaining such increased efﬁcacy per Gy (for
review [29]).
Here, we investigated whether the higher RIT cytotoxicity per unit
of absorbed dose was due to lack of detection of DNA damage induced
by low dose-rate RIT in p53−/− and p53+/+ HCT116 cells targeted
with 125I-mAbs.
2. Materials and methods
2.1. Cell lines
HCT116 (p53+/+) human colorectal cancer cells were from ATCC.
The p53−/− HCT116 cell line was a gift from Professor Bert Vogelstein
(Johns Hopkins University). HCT116 cells express HER1 and basal
level of CEA receptors. They were grown in RPMI supplemented with
10% heat-inactivated FBS, 100 μg/mL L-glutamine and antibiotics (0.1
unit/mL penicillin and 100 μg/mL streptomycin). A-431 and SK-OV-3
cells were previously described in Ref. [20].
2.2. Antibodies and radiolabelling
The internalizing m225 mAb [19,20] was used for targeting the
epidermal growth factor receptor (EGFR/HER1) expressed in HCT116
and A-431 cells. The internalizing trastuzumab (Herceptin®, Genen-
tech Incorporated, San Francisco, CA, USA) binds to Epidermal
Receptor type 2 (HER2) expressed in SK-OV-3 cells [20] and the
non-internalizing murine IgG1k mAb 35A7 targets CEA in all the cell
lines [19,20]. The non-targeting IgG1 mAb PX was used as control
[19,20]. MAbs were radiolabelled with 125I using the conventional
IODO-GEN method (1,3,4,6-tetrachloro-3α, 6α-diphenylglycoluryl)
described in Ref. [20].
2.3. Cellular dosimetry
The mean nucleus absorbed dose was previously calculated for
HCT116 cells exposed to increasing activities (0–4 MBq/ml) of 125I-
mAbs [19]. Brieﬂy, the MIRD cellular approach [30] that requires the
determination of the total cumulative number of decays (Ãrs)
occurring in cells and the S-values was used. Then, for each test
activity, radioactivity uptake per cell (Bq/cell) was determined as
described in [20] and used to estimate Ãrs. For all targeting models,
Ãrs was then multiplied by the corresponding S-value to obtain themean nucleus absorbed dose. For S-value calculations, three
sources of irradiation were considered: self-irradiation from
radiolabelled vectors that were internalized in the cytoplasm (anti-
HER1 125I-mAbs) or bound to the cell membrane (anti-CEA 125I-mAbs);
culture medium irradiation from unbound radiolabelled vectors; and
cross-ﬁre irradiation. Cell size was measured by ﬂuorescence micros-
copy after propidium iodide staining and the cell radius (distributed
normally within the HCT116 cell population) was 5.6 ± 1.0 μm
when the nucleo-cytoplasmic ratio was about 0.65. The cellular
radioactivity was assumed to be uniformly distributed within
cytoplasm and at cell surface for internalizing and non-internalizing
125I-mAbs, respectively.
2.4. Alkaline single-cell gel electrophoresis
The alkaline single-cell gel electrophoresis assay (comet assay)
was used to measure DNA damage in 3 × 105 HCT116 cells grown in
6-well plates and exposed to 0 and 4 MBq/mL of 125I-mAbs. The
comet assay was carried out either i) under standard RIT conditions
(i.e., cells at 37 °C for the entire RIT duration) at different time points
(15 min, 1 h, 2 h, 3 h, 6 h, 12 h, 24 h and 48 h), or ii) following pre-
incubation of cells in cold medium at 4 °C for 1 h and RIT at 4 °C for
4 h. Samples were collected at 15 min, 30 min, 1 h, 2 h, 3 h and 4 h
after RIT onset. For both conditions (37 °C and 4 °C), the methodology
described in [31] was used. The tail moment (TM) was the parameter
retained for analysis. The mean TM, expressed in arbitrary units (a.u.),
was measured in 100 randomly chosen cells per slide for each time
point and was calculated with the Comet Imager 2.0 software
(Metasystems, Hamburg, Germany). Three slides for each condition
and each time point were analyzed per experiment and experiments
were repeated three times.
2.5. Micronucleus assay
3 × 104 HCT116 cells were seeded in 24-well plates. HCT116 cells
exposed to activities between 0 and 4 MBq/mL of 125I-mAbs for
2 days. Twenty-four hours before selected time points (day 1, day 2
and 3 post onset of RIT), cytochalasin B was added to the culture
medium at a ﬁnal concentration of 5 μg/mL in order to block
cytokinesis and was maintained for 24 hours. Cells were then
harvested and centrifuged. Supernatant was carefully discarded and
the pellet was treated with KCl 125 mM under constant shaking for
hypotonic chock. Cells were then ﬁxed three times in acetic acid:
ethanol (1:6), dropped onto slides under humidiﬁed atmosphere and
air dried. Before analysis, slides were stained with propidium iodide
(500 μg/mL). Experiments were repeated three times in triplicate.
2.6. Protein extraction and Western blotting
5 × 105 HCT116 and 4 × 105 A-431 and SK-OV-3 cells were grown
in 6-well plates and exposed to 0 and 4 MBq/mL of 125I-mAbs for
2 days. Proteins were extracted as described in [19]. Membranes were
pre-incubated with 5% milk in PBS/0.1% Tween 20 and then with anti-
p53 (1:10,000), -p21 (1:500) (Santa Cruz Biotechnology, CA, USA),
-gamma-H2AX (1:1000) (Merck Millipore, Guyancourt, France) or p-
ATM (1:1000) (Cell Signaling Technology, Danvers, MA, USA) primary
antibodies, followed by horseradish peroxidase-conjugated anti-
rabbit secondary antibodies (1:10,000; Sigma-Aldrich, Saint-Louis,
MO, USA). GAPDH level was used to evaluate protein loading. Levels of
protein expressionwere quantiﬁed using the G-Box system (Syngene;
Cambridge UK).
2.7. Gamma-H2AX immunoﬂuorescent measurement
For double strand breaks formation, 2 × 104 cells were grown on
cover slip and were exposed for 2 days to 0 and 4 MBq/mL of 125I-
Fig. 1. DNA damage in p53+/+ (panel A) and p53−/− (panel B) HCT116 cells after RIT at 37 °C. The alkaline comet assay was used to measure DNA damage at various time points
(15 min and then 1, 2, 3, 6, 12, 24 and 48 h) in HCT116 cells targeted with 0 or 4 MBq/mL of internalizing anti-HER1 (m225), non-internalizing anti-CEA (35A7)) or non-targeting
(PX) 125I-mAbs at 37 °C (standard RIT conditions). The mean TM of 100 randomly chosen cells per slide was calculated using the Comet Imager 2.0 software. Three slides were
analyzed per each condition and time point and experiments were repeated three times.
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formaldehyde in PBS for 30 min. They were then permeabilized at
room temperature for 30 min using PBS/Triton (0.5%). Cells were
next washed twice with PBS, saturated with PBS/BSA (1 mg/ml) for
1 hour before incubation overnight with anti-gamma-H2AX (1:200
PBS/BSA; Merck Millipore). Next, cover slips were incubated for 1 h
in the dark with FITC-labeled goat anti-mouse Ig (Sigma) in PBS-Fig. 2. DNA damage in p53+/+ (panel A) and p53−/− (panel B) HCT116 after RIT at 4 °C. The
30 min and then 1, 2, 3 and 4 h) in HCT116 cells exposed to 4 MBq/mL of internalizing ant
4 °C. TMwasmeasured as a function of themean nucleus absorbed dose, but only during 4 ho
calculated using the Comet Imager 2.0 software. Three slides were analyzed per each condiBSA and next washed three times with PBS-BSA and once with PBS
before analysis.
2.8. Cell cycle
20 × 104 HCT116 cells were grown in 6-well plates one day
before RIT. Cells were harvested at day 0, 1, 2, 3, 4 and 7 of RIT byalkaline comet assay was used to measure DNA damage at various time points (15 min,
i-HER1 (m225), non-internalizing anti-CEA (35A7) or non-targeting (PX) 125I-mAbs at
urs in order to keep cells alive. Themean TM of 100 randomly chosen cells per slide was
tion and time point and experiments were repeated three times.
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70% ethanol at−20 °C for 3 hours and stained with cell cycle kit
reagent from Merck Millipore (Merck Millipore, Guyancourt,
France) in the dark for 30 min at room temperature before
analysis using an Muse® ﬂow cytometer (Merck Millipore,
Guyancourt, France). The percentage of cells in G0/G1, S and
G2/M phases was then calculated (mean of three experiments
in triplicate).
2.9. Statistical analysis
The linear mixed regression model (LMRM) [20] was used for
statistical analysis of the data.Fig. 3. Activation of DNA damage-related signaling proteins. The level of phosphorylated A
indicated time points in HCT116 cells exposed to 0 and 4 MBq/mL of internalizing anti-HER1
(bottom). Panel A: p53+/+ HCT116 cells and panel B: p53−/− HCT116 cells.3. Results
3.1. DNA damage formation and repair occur simultaneously during RIT
We investigated the occurrence of DNA single (SSBs) and double
(DSBs) strand breaks and alkali-labile sites (ALSs) in p53+/+ and p53−/−
HCT116 cells upon exposure to 4 MBq/mLof anti-CEA (35A7), anti-HER1
(m225) or non-targeting (PX) 125I-mAbs for 2 days. The mean nucleus
doses were calculated [19] using the MIRD cellular formalism. Under
standard RIT conditions (at 37 °C), occurrence of DNA damage (as
indicatedby theTMparameter)wasnot signiﬁcantly different inHCT116
cells treated with anti-HER1 or anti-CEA 125I-mAbs in comparison to
untreated cells (p = 0.85 and p = 0.72, respectively) (Fig. 1).TM (p-ATM) and H2AX (gamma-H2AX), p53 and p21 proteins was measured at the
(m225), non-internalizing anti-CEA (35A7) 125I-mAbs. GAPDH served as loading control
e79B. Piron et al. / Nuclear Medicine and Biology 41 (2014) e75–e83This ﬁnding suggests that radiation-induced DNA damage
formation was compensated by DNA repair during RIT. In order to
conﬁrm this hypothesis, we investigated the level of DNA breaks in
cells incubated with 125I-mAbs at 4 °C for 4 h (instead of 48 h at
37 °C as used under standard RIT). Temperature of 4 °C is known to
block enzymatic systems involved in DNA breaks repair. The 4 h
exposure time was determined as the longest time of exposure at
4 °C producing no cytotoxicity. We observed under these conditions
a progressive increase in DNA damage in p53+/+ and p53−/−
HCT116 cells exposed to anti-CEA and anti-HER1 125I-mAbs in
comparison to those treated with non-targeting 125I-mAbs (Fig. 2A
and B). These data conﬁrmed that DNA repair occurred during
standard RIT while DNA breaks accumulated at 4 °C. We next
calculated, the corresponding absorbed doses delivered to the
nucleus by 4 MBq/mL 125I-mAbs. We thus considered the cumula-
tive number of decays (Ãrs) calculated over 4 h (and not 48 h like
under standard RIT). We also considered that internalization of
mAbs was blocked at 4 °C such that S-values for cell surface
localization were used for internalizing mAbs. Absorbed doses were
then shown to be lower than under standard RIT (anti-HER1 125I-Fig.4. Immunoﬂuorescent detection of gamma-H2AX in cells. Cells were grown on cover slip
detected at various time in (A) p53+/+ and (B) p53−/− following onset of exposure to 125ImAbs: from 43 Gy at 37 °C to 1.92 Gy at 4 °C; anti-CEA 125I-mAbs:
from 1.20 Gy to 0.1 Gy; non-targeting 125I-mAbs from 0.27 Gy to
0.015). Corresponding highest TM values were 12.8 (anti-HER1 125I-
mAbs), 6.0 (anti-CEA 125I-mAbs) and 2.8 (non-targeting 125I-mAbs)
a.u. in p53+/+ HCT116 cells and 10.4 (anti-HER1 125I-mAbs), 5.9
(anti-CEA 125I-mAbs) and 4.5 (non-targeting 125I-mAbs) a.u. in
p53−/− cells. In cells exposed to anti-HER1 125I-mAbs, TM
increased linearly as a function of the absorbed dose in both
p53+/+ and p53−/− HCT116 cells (p b 0.001). Following exposure to
anti-CEA 125I-mAbs, TM increase was linear in p53+/+ HCT116 cells
(p b 0.007), but not in p53−/− cells (p = 0.103), where it exhibited a
larger standard error (Fig. 2A and B). However, comparison of the
efﬁcacy of anti-CEA and anti-HER1 125I-mAbs showed that, overall, they
produced quantitatively similar effects in both p53−/− (p = 0.251) and
p53+/+ (p = 0.172) HCT116 cells, because anti-CEA 125I-mAbs (with
lower mean nucleus absorbed doses) were more efﬁcient per Gy than
anti-HER1 125I-mAbs (with higher mean absorbed doses) in producing
DNA damage. Moreover, the effect of each antibody was similar in the
two cell lines (p = 0.681 for anti-CEA 125I-mAbs andp = 0.372 for anti-
HER1 125I-mAbs).and exposed for 2 days to 0 and 4 MBq/mL of 125I-mAbs. Gamma-H2AX foci were next
-mAbs.
e80 B. Piron et al. / Nuclear Medicine and Biology 41 (2014) e75–e833.2. DNA damage-mediated signaling pathways are efﬁciently activated
in HCT116 cells
Under standard RIT conditions, the comet assay results suggested
activation of DNA repair mechanisms. We thus assessed whether such
low levels of RIT-induced DNA damage could activate ATM, H2AX and
p53 (one of the key proteins of the radiation response) (Fig. 3).
Western blot analysis revealed that phosphorylated ATM (p-ATM)
and p53 level increased in p53+/+ HCT116 cells exposed to RIT at
37 °C and were associated with p21 up-regulation (Fig. 3A). The
extent of their induction was not correlated with the nucleus
absorbed dose because it was only slightly higher upon exposure to
anti-HER1 125I-mAbs than to anti-CEA 125I-mAbs, although much
different doses were delivered to the nucleus (43 Gy versus 1.2 Gy).
Detection of gamma-H2AX indicated that DNA DSBs were continu-
ously produced under standard RIT conditions (Fig. 3A), while no
increase could be observed using the comet assay which detects all
kind of breaks (DSBs + SSBs + ALSs). Similar results were obtained
in p53−/− HCT116 cells for p-ATM, gamma-H2AX, and p21 (Fig. 3B).
Activation of p53 was also observed in A-431 (p53+/+), but not in
SK-OV-3 (p53−/−) cells exposed to 125I-mAbs (Supplementary Fig. 1).
These two cell lines are more sensitive to non-internalizing anti-CEA
than to internalizing anti-HER1/HER2 125I-mAbs [20]. In HCT116 and
A-431 cells, p53 up-regulation is followed by induction of apoptosis at
day 2 post-RIT [19]. These results suggest that the DNA damage
induced by mean nucleus absorbed doses as low as 1.2 Gy can be
efﬁciently detected in cells exposed to RIT.
The p21 protein up-regulation measured in HCT 116 cells was
accompanied by cell cycle arrest in G2/M phase in both p53+/+ andFig. 5. Micronucleus (MN) frequency. p53+/+ (panel A) and p53−/− (panel B) HCT116 c
internalizing anti-CEA (35A7) or non-targeting (PX) 125I-mAbs. Micronuclei (MN) occurre
cumulative MN frequency during the three days was determined.p53−/− cells upon exposure to anti-CEA and anti–HER1 125I-mAbs
(Fig. 6). In both cell lines, the % of cells in G2/Mwas shown to increase
signiﬁcantly at day 1 post onset of RIT up to day 7.
3.3. Double strand breaks detection
Double strand breaks (DSBs) as revealed by gamma-H2AX foci
detection were produced in p53−/− and p53+/+ HCT 116 cells
exposed for 2 days to 4 MBq/mL of either internalizing anti-HER1 or
non-internalizing anti-CEA 125I-mAbs (Fig. 4). DSBs were detected as
early as 6 h post incubation with radiolabeled mAbs and their yield
was continuously increasing in a similar way for both types of mAbs,
independently of the mean nucleus absorbed dose. Moreover, they
were still detected 24 h after the radioactivity was removed, namely
72 h post onset of RIT. These data suggest that DSBs are continuously
formed under RIT using 125I-mAbs and that they are not accurately
repaired and accumulate with time.
3.4. Yield of micronuclei as a function of the mean nucleus absorbed dose
Micronuclei per binucleated cells (MN/BN) were produced in both
p53+/+ and p53−/− HCT116 cells during RIT using 125I-mAbs,
suggesting error-prone DNA repair. In p53+/+ HCT116 cells, their
formation at 24 h post onset of RIT using either internalizing anti-
HER1 or non-internalizing anti-CEA 125I-mAbs was increasing with
the test activity. For non-internalizing 125I-mAbs, yield of MN at
4 MBq/mLwas higher at 24 h (0.34 ± 0.06MN/BN versus 0.14 ±0.06
MN/BN at 0 MBq/mL) than at 48 h (0.20 ± 0.11 MN/BN) and it
decreased to background level at 72 h (0.12 ± 0.08). Similarells were exposed to 0, 1, 2 and 4 MBq/mL of internalizing anti-HER1 (m225), non-
nce was determined in 500 binucleated cells at day 1, 2 and 3 of incubation and the
Fig. 6. Cell cycle analysis. p53+/+ (panel A) and p53−/− (panel B) HCT116 cells were exposed to 0 or 4 MBq/mL of internalizing anti-HER1 (m225), non-internalizing anti-CEA (35A7)
for several days. Cells were collected at day 0, 1, 2, 3, 4 and 7 of RIT, ﬁxed in 70% ethanol for 3 hours and stained with Cell Cycle Kit reagent for analysis by ﬂow cytometry.
Experiments were repeated in triplicate.
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MN/BN at 24 h, 0.22 ± 0.04 MN/BN at 48 h, 0.14 ± 0.12 MN/BN at
72 h). It must be noted that yield of MN/BN in cells treated with non-
speciﬁc 125I-PX mAbs remained at the background level (between
0.08 ± 0.03 and 0.14 ± 0.06MN/BN).
In p53−/− HCT116 cells, relationship between MN yield and test
activity was less pronounced (Fig. 5). This can be partly due to a
higher background level in non-treated cells (around between 0.15
and 0.27MN/BN) and to large uncertainties associated to MN
measurement. Similarly, no clear trend of a decrease between 24 h
and 48 h in MN yield was observed.
4. Discussion
We showed previously in HCT116 cells targeted by 4 MBq/mL of
125I-mAbs (Fig. 7 and Ref. [19]) that a mean nucleus absorbed dose
of 1.2 Gy of non-internalizing anti-CEA 125I-mAbs is as effective as
43 Gy of internalizing anti-HER1 125I-mAbs. As the cell response to
ionizing radiation is generally, in CEBRT, triggered by nuclear DNA
damage, we thus investigated the relationship between the energy
deposited in the nucleus (i.e., the mean nucleus absorbed dose) and
several biological endpoints during RIT with 125I-mAbs. Non-
internalizing anti-CEA 125I-mAbs and, to a lower extent, internal-
izing anti-HER1 125I-mAbs, were very efﬁcient in killing cells [19]
and also in producing DNA damage despite lower dose-rates (about
0.025 Gy.h−1 for anti-CEA 125I-mAbs and 0.9 Gy.h−1 for anti-HER1
125I-mAbs) than in CEBRT (about 2 Gy.min−1). The high efﬁciency
of 125I-mAbs, particularly of anti-CEA 125I-mAbs per unit-dose, is
reminiscent of low-dose hyper-radiosensitivity and of the inverse
dose-rate effect. These two phenomena, which were reported inCEBRT (for review [32]) after low dose (below 0.5 Gy) or low dose-
rate (0.02–1.00 Gy.h−1) exposure, lead to increased effectiveness of
radiation per unit-dose beyond what could be predicted by the
conventional linear and linear quadratic radio-biologic models ([33]
and for review [32]). It has been proposed that they are the result
of decreased sensing of DNA damage by signaling proteins and of
the consequent reduced activation of the early DNA damage
response through ATM and p53 or the G2 checkpoint ([34] and
for review [29]). Our ﬁndings do not support this hypothesis.
Indeed, ATM, H2AX and p21 were efﬁciently activated in p53−/−
and p53+/+ HCT116 cells and p53 expression was also increased (in
p53+/+ HCT116 cells and A-431 cells) during RIT with 125I-mAbs.
Moreover, most of the DNA breaks were immediately repaired
under standard RIT conditions (comet assay data, Figs. 1 and 2).
However, the signiﬁcant increase in expression and accumulation of
gamma-H2AX, due to phosphorylation of H2AX at DSB sites [35] in
cells treated with anti-CEA or anti-HER1 125I-mAbs indicates that
DSBs were continuously formed and not repaired. Consequently,
mis- or un-repaired DSBs might have led to micronuclei formation
(Fig. 4) and to mitotic death of damaged cells. These data indicate
that acute cell death associated with low doses and low dose-rate
of 125I-mAbs (particularly of non-internalizing anti-CEA 125I-mAbs)
was not due to defective detection of DNA damage by the cells.
Impaired repair of double strand breaks would be involved in low
dose rate efﬁcacy of RIT using 125I-mAbs in a non-dependent dose-
effect relationship.
Another intriguing observation is the lack of relationship between
the mean nucleus absorbed doses (in Gy) and these biological
endpoints when comparing the efﬁcacy/Gy of anti-CEA and anti-
HER1 125I-mAbs. In CEBRT, the biological effects and, consequently,
Fig. 7. Survival. Clonogenic survival was assessed in (A) p53+/+ and (B) p53−/− HCT116 cells following exposure to test activities of 125I-mAbs that gradually increased from 0 to
4 MBq/mL for 2 days. Cells were targeted with internalizing anti-HER1 (m225), non-internalizing anti-CEA (35A7) 125I-mAbs. Survival was expressed as a function of (A) the total
cumulative radioactivity uptake Ãrs (B) the mean nucleus absorbed dose. Results are the mean of four experiments done in triplicate (from Paillas et al. [19]).
e82 B. Piron et al. / Nuclear Medicine and Biology 41 (2014) e75–e83the survival of irradiated cells are correlated with the mean nucleus
absorbed dose [36], according to a linear or linear quadratic
relationship depending on whether low-LET or high-LET radiations
are used. Here, no linear dose-effect relationship was observed when
the effects per Gy of absorbed dose of anti-CEA and anti-HER1 125I-
mAbs are considered. Indeed, the biological response per Gy of non-
internalizing anti-CEA 125I-mAbs was much higher than that of
internalizing anti-HER1 125I-mAbs. Hence, quantitatively similar
effects were produced by 125I-mAbs with much different nucleus
absorbed doses. This is true for clonogenic survival [27], frequency of
DNA breaks and micronuclei formation, induction of DNA damage
response and effects on cell cycle progression. Based on the
localization of the energy deposits due to decay of anti-CEA 125I-
mAbs at the cell membrane [19] and the lack of correlation between
absorbed dose and biological effects we hypothesize that cell
membrane-mediated 125I-induced bystander effect, as described in
CEBRT ([37–39] and for reviews [29,40]), could play a signiﬁcant role
in the higher efﬁcacy of non-internalizing 125I-mAbs [41–43] and
should be further investigated.
We would like to highlight that the hypersensitivity of HCT116
cells to non-internalizing 125I-mAbs is not dependent on our
dosimetric approach based on MIRD formalism since we showed
that it was still observedwhen survivalwas expressed as a function of
cumulated uptake of radioactivity (Fig. 7A). Moreover, cytoplasmic
and cell surface localizations of m225 and 35A7, respectively, were
conﬁrmed in several cell lines using cell fractionation assays and
immunoﬂuorescence approaches (unpublished data). However, it
must be kept inmind that Bousis et al. showed that for the casewhere
the radiopharmaceutical are either internalized into the cytoplasm or
remained bound onto the cell surface (non-internalized), the dose to
the cell nucleus determined using Monte Carlo code was found to
differ signiﬁcantly from the MIRD values. Then, use of MIRD
formalism with short range Auger electrons emitters must be done
carefully [44].In conclusion, this study shows that DNA damage produced by low
dose of 125I-mAbs is efﬁciently detected by targeted cells even after
very low absorbed dose, but is associated to accumulation of DNA
double strand breaks. G2/M cell cycle arrest does not prevent
damaged cells still proceed through cell cycle and to undergo mitotic
death. The lack of dose-effect relationship between mean nucleus
absorbed dose and several biological endpoints and the property of
non-internalizing 125I-mAbs to deliver localized doses at the cell
membrane suggest that cell membrane-mediated bystander effects
might be involved in 125I-mAbs cytotoxicity.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nucmedbio.2014.01.012.
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